Comment on Media Report
Evotec SE has received an unsolicited, non-binding expression of interest from US biotechnology company Halozyme Therapeutics Inc. regarding a potential takeover. The proposed offer price is EUR 11.00 per share. Evotec states that there was no prior contact before this expression of interest. The company will analyze the proposal and inform the capital market about next steps in accordance with legal requirements.
Evotec SE ha ricevuto un'espressione di interesse non vincolante e non sollecitata da parte della società biotecnologica statunitense Halozyme Therapeutics Inc. riguardante un potenziale takeover. Il prezzo dell'offerta proposto è di EUR 11,00 per azione. Evotec dichiara che non ci sono stati contatti precedenti a questa espressione di interesse. La società analizzerà la proposta e informerà il mercato dei capitali sui prossimi passi in conformità con i requisiti legali.
Evotec SE ha recibido una expresión de interés no vinculante no solicitada de la empresa biotecnológica estadounidense Halozyme Therapeutics Inc. respecto a una posible adquisición. El precio propuesto por acción es de EUR 11,00. Evotec informa que no hubo contacto previo antes de esta expresión de interés. La empresa analizará la propuesta e informará al mercado de capitales sobre los próximos pasos de acuerdo con los requisitos legales.
Evotec SE는 미국 생명공학 회사 Halozyme Therapeutics Inc.로부터 비구속적인 관심 표현을 예기치 않게 받았습니다. 제안된 인수 가격은 주당 11.00 유로입니다. Evotec은 이 관심 표현 이전에 연락이 없었다고 밝혔습니다. 회사는 이 제안을 분석하고 법적 요구 사항에 따라 자본 시장에 다음 단계를 알릴 것입니다.
Evotec SE a reçu une manifestation d'intérêt non sollicitée et non contraignante de la part de la société biopharmaceutique américaine Halozyme Therapeutics Inc. concernant une éventuelle prise de contrôle. Le prix proposé est de 11,00 EUR par action. Evotec indique qu'il n'y a pas eu de contact préalable avant cette manifestation d'intérêt. L'entreprise analysera la proposition et informera le marché des capitaux des prochaines étapes conformément aux exigences légales.
Evotec SE hat ein unverbindliches Interesse von der US-Biotechnologiefirma Halozyme Therapeutics Inc. erhalten, das einen potenziellen Übernahmeversuch betrifft. Der vorgeschlagene Angebotspreis beträgt 11,00 EUR pro Aktie. Evotec gibt an, dass es vor dieser Interessensbekundung keinen Kontakt gab. Das Unternehmen wird den Vorschlag prüfen und den Kapitalmarkt gemäß den gesetzlichen Anforderungen über die nächsten Schritte informieren.
- Potential takeover offer at EUR 11.00 per share indicates market interest in the company
- Interest from established US biotech company could lead to strategic opportunities
- Unsolicited nature of the offer might indicate lack of alignment with company's strategic plans
- Non-binding status creates uncertainty for shareholders
Insights
This unsolicited takeover interest from Halozyme at
The non-binding nature of the expression of interest means there's no certainty of a deal materializing. Key considerations for Evotec's board will include valuation adequacy, strategic fit and potential synergies. Halozyme's ENHANZE drug delivery technology could complement Evotec's drug discovery capabilities, potentially creating a more comprehensive drug development platform.
Shareholders should note that this is very preliminary and the board has significant fiduciary duties to evaluate any proposal thoroughly. The lack of prior contact suggests this could be the opening move in what might become a longer negotiation process.
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the proposed takeover price per share for Evotec (EVO) by Halozyme?
Is Halozyme's takeover offer for Evotec (EVO) binding?
When did Evotec (EVO) receive the takeover interest from Halozyme?
How did Evotec (EVO) respond to Halozyme's takeover interest?
